Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Buy” from Analysts

Aura Biosciences, Inc. (NASDAQ:AURA) has received a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $23.00.

A number of analysts have commented on AURA shares. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 23,045 shares of company stock valued at $177,242 in the last quarter. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently modified their holdings of AURA. SG Americas Securities LLC purchased a new position in shares of Aura Biosciences in the 3rd quarter valued at about $169,000. Charles Schwab Investment Management Inc. increased its stake in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after purchasing an additional 3,612 shares in the last quarter. State Street Corp increased its stake in shares of Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Aura Biosciences in the 3rd quarter valued at about $1,037,000. Finally, Barclays PLC increased its stake in shares of Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after purchasing an additional 43,897 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Stock Performance

Shares of AURA opened at $7.50 on Thursday. The stock has a 50-day moving average of $7.93 and a two-hundred day moving average of $8.72. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38. The stock has a market cap of $374.63 million, a P/E ratio of -4.34 and a beta of 0.29.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.